Effect of Granulocyte-Monocyte Colony-Stimulating Factor Therapy on Leukocyte Function and Clearance of Serious Infection in Nonneutropenic Patients

Autor: Nicole Penkosky, Mark H Cohen-Melamed, Adrienne M. Dorrance, Peter K. Linden, Michael R. Pinsky, Alan J. Rosenbloom
Rok vydání: 2005
Předmět:
Adult
Male
Pulmonary and Respiratory Medicine
Colony-Stimulating Factor Therapy
Critical Care and Intensive Care Medicine
Risk Assessment
Severity of Illness Index
Drug Administration Schedule
Monocytes
Proinflammatory cytokine
Sepsis
Reference Values
Leukocytes
medicine
Humans
Single-Blind Method
Prospective Studies
Infusions
Intravenous

Aged
Probability
Dose-Response Relationship
Drug

biology
Tumor Necrosis Factor-alpha
business.industry
Monocyte
Granulocyte-Macrophage Colony-Stimulating Factor
Middle Aged
Flow Cytometry
medicine.disease
Survival Analysis
Up-Regulation
Granulocyte colony-stimulating factor
Systemic inflammatory response syndrome
Treatment Outcome
medicine.anatomical_structure
Integrin alpha M
Immunology
biology.protein
Female
L-selectin
Cardiology and Cardiovascular Medicine
business
Follow-Up Studies
Zdroj: Chest. 127:2139-2150
ISSN: 0012-3692
Popis: Study objective Impaired leukocyte function in patients with serious infections may increase mortality. Granulocyte-monocyte colony-stimulating factor (GM-CSF) broadly activates peripheral monocytes and neutrophils. We performed a clinical trial of GM-CSF in septic, hemodynamically stable patients to see whether GM-CSF treatment improved leukocyte function and mortality. Design Randomized, unblinded, placebo-controlled, prospective study. Setting A 600-bed academic tertiary care center with a 120-bed ICU census with a high proportion of immunocompromised, solid-organ transplant recipients. Patients Forty adult patients with infections meeting the criteria for the systemic inflammatory response syndrome but without hemodynamic instability or shock. Interventions Patients with sepsis and a documented infection were randomized to a 72-h infusion of GM-CSF (125 μg/m 2 ) or placebo. Measurements and main results GM-CSF infusion caused the up-regulation of the β 2 -integrin adhesion molecule CD11b and the appearance of the activated (“sticky” or “avid”) form of the molecule on circulating neutrophils and monocytes. CD11b density and avidity increases in response to the administration of tumor necrosis factor-α were blunted prior to treatment in these patients with serious infection. GM-CSF partially repaired this blunted response on both monocytes and neutrophils. It also caused the down-regulation of the adhesion molecule L-selectin on neutrophils and the up-regulation of human leukocyte antigen on monocytes. These changes were consistent with a broad activation of the circulating leukocyte pool. Although mortality and organ failure scores were similar in both groups, infection resolved significantly more often in patients receiving GM-CSF. Conclusions GM-CSF infusion up-regulated the functional markers of inflammation on circulating neutrophils and monocytes and was associated with both the clinical and microbiological resolution of infection. There was no detectable exacerbation of sepsis-related organ failure or other deleterious side effects with the administration of this proinflammatory agent to patients with serious infections.
Databáze: OpenAIRE